VR for Symptom Control and Wellbeing

NCT04821466 | Completed DMC

• 1 other identifier: 2021.RCHT.07
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

To investigate the effect that a Virtual Reality experience can have on patient symptoms and wellbeing for palliative care and oncology inpatients

Conditions

Oncology; End Stage Cancer; Palliative Care; Hematologic Malignancy

Keywords

Virtual Reality

Outcome Measures

Primary Outcomes (1)

• ESAS-r Quality of Life Scores

  Change in ESAS-r QoL score between start and finish of Virtual Reality experience. 0 = No symptoms to 10 = Worst Symptom

  Time 0 & Time 60 minutes

Secondary Outcomes (2)

• Quantitative clinician experience of VR intervention

  Time 60 minutes

• Quantitative clinician experience of VR intervention

  Time 60 minutes

Other Outcomes (2)

• Qualitative patient experience of VR interventions

  Time 60 minutes

• Repeat VR experiences

  12 Months

Study Arms (1)

Virtual Reality Headset

EXPERIMENTAL

VR headset, programmed with a selection of 7 wellbeing programs to identify if use will improve participants wellbeing

Device: Virtual Reality Headset to provide a Virtual Reality Experience

Interventions

Virtual Reality Headset to provide a Virtual Reality Experience DEVICE

Participants will utilise a Virtual Reality experience for distraction therapy via a Virtual reality headset. Participants will wear the Virtual reality headset to be immersed in a multimedia experience.

Virtual Reality Headset

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \> 18 years of age
• Inpatient at RCHT know to the palliative care team
• Able to consent
• Able to speak and understand the English language
• Able to use the virtual reality system
• Able to complete ESAS-r Questionnaire

You may not qualify if:

• \<18 years of age
• Patient unable to consent
• Patient unable to speak English
• Unable to use the virtual reality system (e.g. visually impaired)
• Known Epilepsy or seizures or suspected predisposition to seizures (e.g. Brain metastasis)

Sponsors & Collaborators

• Royal Cornwall Hospitals Trust: lead

Study Sites (1)

Royal Cornwall Hospital

Truro, Cornwall, TR1 3HD, United Kingdom

Location

Related Publications (1)

• Moon NO, Henstridge-Blows JR, Sprecher EA, Thomas E, Byfield A, McGrane J. 'Godrevy Project': virtual reality for symptom control and well-being in oncology and palliative care - a non-randomised pre-post interventional trial. BMJ Oncol. 2023 Dec 18;2(1):e000160. doi: 10.1136/bmjonc-2023-000160. eCollection 2023.

  PMID: 39886490 DERIVED

MeSH Terms

Conditions

Neoplasms; Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Niall O Moon, BMBCh

  Doctor

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Cohort interrupted time series study

Study Record Dates

• First Submitted: March 23, 2021
• First Posted: March 29, 2021
• Study Start: June 14, 2021
• Primary Completion: September 20, 2022
• Study Completion: September 20, 2022
• Last Updated: November 21, 2023

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)